Gastrointestinal Stents Market: as EUS-guided biliary drainage accumulates published clinical evidence showing comparable or superior outcomes to conventional ERCP in select patients, the procedural map for treating malignant biliary obstruction is genuinely widening beyond endoscopists trained solely in traditional cannulation technique, so stent manufacturers positioning specifically for this EUS-BD pathway are competing for a different, growing pool of procedures rather than simply taking share from the established ERCP-delivered stent base, and clinical evidence quality is what will determine how fast that pathway scales.

The global gastrointestinal stents market size was USD 504 Million in 2025 and is expected to register a revenue CAGR of 5.2% during the forecast period. Market revenue growth is driven by factors such as Olympus' integration of Taewoong Medical's stent portfolio establishing a combined endoscope-and-stent platform, expanding FDA-approved indications for established biliary stent franchises, and accumulating clinical evidence supporting EUS-guided biliary drainage as an alternative to conventional ERCP. The first driving factor is Olympus' integration of Taewoong Medical's NITI-S self-expanding metal stent portfolio into a combined endoscope-and-stent commercial platform following the January 2024 acquisition close. Biliary stents account for approximately 44% of total 2025 market revenue, reflecting biliary obstruction's position as the most common indication across this product category. The second driving factor is expanding FDA-approved indications for established biliary stent franchises, broadening the patient population eligible for stent-based rather than surgical management of biliary obstruction. The third driving factor is accumulating clinical evidence supporting EUS-guided biliary drainage as a viable alternative to conventional ERCP in select patients. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way accumulating published clinical evidence for a specific procedural pathway, such as EUS-guided biliary drainage, widens the population of patients and treating physicians who can appropriately use that pathway, which converts a niche technique into a broader standard-of-care option without requiring any single new device approval. Because physician adoption of a less familiar procedural pathway like EUS-guided biliary drainage depends heavily on published comparative evidence against the established alternative, each additional peer-reviewed study demonstrating comparable or superior outcomes lowers the evidence-based barrier for the next physician or centre considering adoption, so clinical evidence accumulation compounds adoption momentum independent of any single stent manufacturer's marketing effort. As a result, demand and revenue share are concentrating around stent platforms specifically engineered and positioned for EUS-guided drainage applications, and the forecast tilts toward manufacturers who can point to a growing published evidence base supporting their platform's use in this expanding procedural pathway. For instance, a 2025 publication in Endoscopy International Open found that EUS-guided biliary drainage with a metal stent achieved comparable or superior outcomes to conventional ERCP in select patients, adding to the published evidence base supporting this alternative procedural pathway. These are some of the key factors driving revenue growth of the market.

Because stent migration and tumor or tissue ingrowth causing re-obstruction remain documented limitations even for the newest covered stent designs, physicians must weigh a stent's expected patency duration against the invasiveness of a repeat procedure when a stent fails, which continues to shape technique and product selection even as newer designs improve on older ones.

Device-related safety events are a second constraint, because even long-established, market-leading stent platforms can experience manufacturing or design issues serious enough to trigger regulatory action, which introduces real uncertainty into purchasing and clinical confidence independent of a platform's overall track record.

Personalised stent selection complexity is a third constraint, since a 2024 meta-analysis published in Digestive Endoscopy found that covered self-expanding metal stents provide longer patency for malignant biliary obstruction but that optimal stent selection increasingly requires individualised clinical judgment rather than a single default choice, adding decision complexity for less experienced endoscopists.

These factors substantially limit gastrointestinal stents market growth over the forecast period.

The clearest driver of demand is Olympus' integration of Taewoong Medical's NITI-S self-expanding metal stent portfolio into a combined endoscope-and-stent commercial platform. A hospital or endoscopy centre that already sources its endoscopes and visualization systems from a single manufacturer has a natural procurement incentive to source compatible stent products from the same relationship where clinically appropriate, so combining an established endoscope franchise with a broad stent portfolio under one commercial roof extends that relationship's addressable spend across an entire GI stenting product line. Biliary stents account for approximately 44% of total 2025 market revenue, and Olympus completed its USD 370 million acquisition of Taewoong Medical in January 2024, integrating NITI-S biliary, esophageal, duodenal, and colonic self-expanding metal stents into its Therapeutic Solutions division. The effect on the market is that Olympus is positioned to compete for GI stent purchasing decisions across the full breadth of anatomical indications as an extension of its existing endoscope commercial relationships. These are some of the key factors driving revenue growth of the market.

The second driver is expanding FDA-approved indications for established biliary stent franchises, which broadens the patient population eligible for stent-based rather than surgical management of biliary obstruction. A stent platform's addressable patient population is directly bounded by its labeled indications, so regulatory approval expanding a covered stent's use from narrow malignant obstruction criteria to a broader range of biliary conditions directly converts previously ineligible patients into addressable stent candidates without requiring a new device design. Boston Scientific received expanded FDA approval for its WallFlex Biliary RX Stents covering broader malignant biliary obstruction indications, while its WallFlex Fully Covered Self-Expanding Metal Stent remains the only FDA-cleared covered stent specifically for benign biliary stricture management related to chronic pancreatitis. The effect on the market is that established stent franchises can grow revenue by expanding their labeled indication set on an already-proven platform, without the cost and risk of an entirely new device development programme. These are some of the key factors driving revenue growth of the market.

Biliary stents already account for approximately 44% of 2025 gastrointestinal stents market revenue. A 2025 publication in Endoscopy International Open adding to the evidence base for EUS-guided biliary drainage could meaningfully widen who performs this procedure and how often.

The third driver is accumulating clinical evidence supporting EUS-guided biliary drainage as a viable alternative to conventional ERCP in select patients, widening the procedural pathway for stent placement beyond traditional cannulation-based technique. Conventional ERCP-based biliary stenting requires successful cannulation of the bile duct through the papilla, which can fail in patients with altered anatomy or difficult access, so an EUS-guided approach that bypasses the papilla entirely offers a genuine alternative pathway for patients where conventional ERCP is technically difficult or has already failed. A 2025 publication in Endoscopy International Open found that EUS-guided biliary drainage with a metal stent achieved comparable or superior outcomes to ERCP in select patients, building on a 2024 meta-analysis in Digestive Endoscopy that found covered self-expanding metal stents provide longer patency for malignant biliary obstruction with increasingly personalised stent selection guidance. The effect on the market is that stent manufacturers positioning specifically for the EUS-guided drainage pathway are competing for a genuinely growing procedure population, not simply redistributing share within the existing ERCP-delivered stent base. These are some of the key factors driving revenue growth of the market.

However, the gastrointestinal stents market faces severe adoption constraints from stent migration and re-obstruction rates that limit long-term patency, and from device-related safety events affecting even established stent platforms.

Because stent migration and tumor or tissue ingrowth causing re-obstruction remain documented limitations even for the newest covered stent designs, physicians must weigh a stent's expected patency duration against the invasiveness of a repeat procedure when a stent fails, which continues to shape technique and product selection even as newer designs improve on older ones.

Device-related safety events compound this, because even long-established, market-leading stent platforms can experience manufacturing or design issues serious enough to trigger regulatory action, which introduces real uncertainty into purchasing and clinical confidence independent of a platform's overall track record.

Personalised stent selection complexity is the third constraint, since the 2024 Digestive Endoscopy meta-analysis found that optimal stent selection increasingly requires individualised clinical judgment rather than a single default choice, adding decision complexity for less experienced endoscopists even as the evidence base for personalisation grows.

These factors substantially limit gastrointestinal stents market growth over the forecast period.

Based on product, the global gastrointestinal stents market is segmented into biliary, esophageal, colonic, duodenal, and pancreatic stents. Biliary stents hold the largest revenue share, because biliary obstruction from malignant and benign causes represents the single most common GI stenting indication, which suits a market where the highest-volume clinical indication commands the largest revenue category. Esophageal stents remain established for malignant dysphagia palliation and benign stricture management, with Boston Scientific's WallFlex and comparable covered SEMS designs anchoring this segment. Pancreatic stents are expected to register the fastest revenue growth rate in the global gastrointestinal stents market over the forecast period, driven by expanding EUS-guided pancreatic pseudocyst drainage applications, which is why manufacturers continue to pursue new labeled indications specifically for this anatomical category.

Based on material, the global gastrointestinal stents market is segmented into plastic and polyethylene stents, self-expanding metal stents, and silicone-coated covered stents. Self-expanding metal stents hold the largest revenue share, because they provide longer patency than plastic alternatives for malignant obstruction, which ties directly back to the biliary disease burden described in the market's primary demand driver. Silicone-coated covered stents are expected to register the fastest revenue growth rate in the global gastrointestinal stents market over the forecast period, driven by their combination of metal stent patency with reduced tissue ingrowth risk and improved removability, which is why manufacturers increasingly prioritise covered designs across their newest product launches.

EUS-guided biliary and pancreatic drainage application is expected to register the fastest revenue growth rate in the global gastrointestinal stents market during the forecast period

Based on application, the global gastrointestinal stents market is segmented into biliary disease, colorectal cancer and colonic obstruction, esophageal stricture and dysphagia palliation, and EUS-guided biliary and pancreatic drainage. Biliary disease holds the largest revenue share, reflecting the volume of biliary obstruction cases across both malignant and benign causes. EUS-guided biliary and pancreatic drainage is expected to register the fastest revenue growth rate in the global gastrointestinal stents market over the forecast period, driven by accumulating clinical evidence supporting this pathway as a viable alternative to conventional ERCP, which is why this application represents the category's most closely watched growth opportunity among clinical researchers and manufacturers alike.

Based on regional analysis, the gastrointestinal stents market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of interventional GI programmes and academic medical centres publishing comparative EUS-guided drainage outcome data sustains both the highest stenting procedure volume and the deepest clinical evidence base globally, and because Boston Scientific, Olympus, and Cook Medical all maintain their primary commercial presence in the US market. The scale of US biliary and pancreatic disease treatment volume anchors a domestic stent market large enough to sustain multiple competing platforms simultaneously.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. European academic centres have contributed meaningfully to the EUS-guided biliary drainage evidence base, including comparative studies published in European gastroenterology journals. The result is steady rather than rapid growth, shaped more by national health system reimbursement negotiation than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. South Korea and Japan represent two of the most established national markets within the region, reflecting Taewoong Medical's Korean manufacturing base and Olympus' Japanese corporate headquarters. China's rapidly expanding GI disease treatment infrastructure leaves considerably more room for growth than in the already stent-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private hospital networks driving early adoption of advanced stent platforms among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the nitinol alloy and precision delivery system components that Latin American device distributors depend on, an effect expected to run through 2026 and slow gastrointestinal stent adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding oncology and gastroenterology treatment infrastructure and the UAE's regional distribution hubs represent the primary investment centres for gastrointestinal stent adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the interventional endoscopy infrastructure needed to support advanced stent platforms at scale.